Results 141 to 150 of about 718,683 (284)

Integrative proteomics reveals MSH6 to modulate PARP inhibitor sensitivity in BRCA1/2-proficient ovarian cancer. [PDF]

PLoS One
Deng O, Nepomuceno TDC, Fang B, Welsh EA, Izumi V, Martin RH, George EM, Koomen JM, Monteiro AN, Rix U.   +9 more
europepmc   +1 more source

Synthesis, Cytotoxicity, and Apoptosis‐Associated Cell Death Activity of an Isatin‐Containing Pyrimidine‐Derived Cu(II) Complex

Journal of Applied Toxicology, EarlyView.
ABSTRACT A Cu(II) complex derived from a pyrimidine with the isatin group was synthesized and tested for its cytotoxic effects on A549 lung cancer and MCF‐7 breast cancer cell lines, as well as its effects on apoptosis‐associated cell death and cell cycle regulation in A549 cells. To evaluate cytotoxicity, MTT assays were performed at 24, 48, and 72 h,
Müjgan Kesik Oktay, Cansu Topkaya, Elif Kağa, Yasin Eren, Ramazan Güp   +4 more
wiley   +1 more source

PARP inhibitor YCH1899 activates type I interferon signaling and synergizes with STING agonists in BRCA-proficient tumors. [PDF]

Mol Biomed
Jia L, Cao MH, Sun YT, Bao XB, Zhu WT, Cheng YJ, Wang LM, Yang H, Song SS, Tian CQ, Miao ZH, Yang CH, He JX.   +12 more
europepmc   +1 more source

A PARP inhibitorok hatásának vizsgálata humán keratinociták differenciációjára

A poli(ADP-riboz)iláció egy poszttranszlációs fehérje módosítás, amelyet a poli(ADP-ribóz) polimeráz (PARP) enzimek végeznek. A PARP aktivitás számos biológiai folyamat szabályozásában szerepel, többek között a DNS hibajavítás, transzkripció és ...
Maczkó, Eszter
core  

Anticancer potential of berberine: Molecular pathways and current clinical trial perspectives

JSFA reports, EarlyView.
Abstract Cancer is constantly rising mortality rates due to its late prognosis, poor management, and expensive treatment. Multi‐sectoral approaches for cancer management include hygienic practices, synthetic drug exploitation, radiation therapy, and diet modifications.
Muhammad Maaz, Muhammad Tauseef Sultan, Muhammad Israr, Waqas Ahmad Khan, Fahad Tanveer, Muzzamal Hussain, Muhammad Imran, Ahmed Mujtaba, Anjuman Gul Memon, Muhammad Atif, Entessar Al Jbawi   +10 more
wiley   +1 more source

Rucaparib - drug evaluation: a PARP inhibitor for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer. [PDF]

Future Oncol
Bryce AH, Nash P, Roessler A, Mandair D.
europepmc   +1 more source

Roles of VRK3 in regulation of PARP1 stability and PARP inhibitor sensitivity

, 2018
Poly(ADP-ribose) polymerase 1 (PARP1) is one of the most critical protein in DNA repair response and is highly expressed in breast and ovarian cancer cell.
KIM, KYONG TAI, HAN, SEUNG HYUN
core  

Early Dapagliflozin and Melatonin Treatment Ameliorated LV Fibrosis via Suppressing TGF‐β1/Smads and Activating Nrf2‐ARE Signaling in MI Rodent

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT This study tested whether combined dapagliflozin (DAPA) and melatonin (Mel) therapy was superior to merely one for ameliorating the left ventricular (LV) fibrosis/remodeling and improving LV ejection fraction (LVEF) in rats after acute myocardial infarction (AMI). In vitro study demonstrated that DAPA treatment significantly suppressed the TGF‐
Jiunn‐Jye Sheu, Jui‐Ning Yeh, Han‐Tan Chai, John Y. Chiang, Chi‐Ruei Huang, Jun Guo, Hon‐Kan Yip   +6 more
wiley   +1 more source

Characterizing Response to PARP Inhibitor Treatment Combinations in Advanced Prostate Cancer. [PDF]

Biomedicines
Correa Gonzalez B, Karthikeyan A, Moore LA, Bhaumik A, Sandoval E, Hardy M, McPherson JD, Li H, Parikh M, Dall'Era M, Gao AC, Lombard AP.   +11 more
europepmc   +1 more source

Hsp90 Inhibition on the Western Blot: N‐Terminal Versus C‐Terminal Inhibitors in Breast Cancer

Medicinal Research Reviews, EarlyView.
ABSTRACT Heat shock protein 90 (Hsp90) is an established and clinically validated anticancer target. By regulating the folding and maturation of diverse client proteins, it is indirectly involved in carcinogenesis. Key breast cancer oncogenic drivers, including estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2, are ...
Jaka Dernovšek, Jernej Cingl, Urša Pečar Fonović, Tihomir Tomašič   +3 more
wiley   +1 more source